Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Market Cap	20.61B +28.2%
Revenue (ttm)	1.83B +22.6%
Net Income	676.48M +27.1%
EPS	0.11 +26.4%
Shares Out	n/a
PE Ratio	30.47
Forward PE	27.44
Dividend	0.04 (1.20%)
Ex-Dividend Date	Sep 22, 2025

Volume	n/a
Open	3.326
Previous Close	3.354
Day's Range	3.326 - 3.336
52-Week Range	2.820 - 4.800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and ...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 9,347
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3KY

Financial Performance

In 2025, FRA:3KY's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.

Financial numbers in CNY